Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

ShangPharma to Build $60 Million Biologics Campus

publication date: Sep 17, 2015
ShangPharma, a Shanghai CRO/CMO, will partner with Qidong Biopharma Industrial Zone to build a $60 million biologics campus, including an R&D facility and state-of-the-art manufacturing plant. The two facilities comprise the first stage in a project that is expected to include multiple phases. ShangPharma's CRO division, ChemPartner, will be responsible for the R&D operation while ShangPharma's CMO division, China Gateway Biologics, will be in charge of the commercial scale manufacturing facility. ShangPharma expects the manufacturing plant to be ready for client projects in 2018. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital